The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 34-38

  Dullaart, Robin P F ^a   Annema, Wijtske ^a   Tio, René A ^a   Tietge, Uwe J F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute coronary syndrome; Atypical chest pain; HDL anti inflammatory function; Non STEMI; STEMI

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; MESSENGER RNA;

ACUTE HEART INFARCTION; AGED; ANTIINFLAMMATORY CAPACITY; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; GENE REPRESSION; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; THORAX PAIN; BLOOD; CHEST PAIN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTOR;

AGED; CHEST PAIN; CHOLESTEROL, HDL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84896105032     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.026     Document Type: Article

References (22)

1. Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839. Prospective Studies Collaboration.
2. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. The Emerging Risk Factors Collaboration.
3. Kappelle P.J.W.H., van Tol A., Wolffenbuttel B.H.R., Dullaart R.P.F. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc Ther 2011, 29:E89-E99.
4. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
5. AIM-HIGH Investigators, Boden W.E., Probstfield J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
6. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
7. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009, 58:2711-2717.
8. Corsetti J.P., Gansevoort R.T., Sparks C.E., Dullaart R.P.F. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 2010, 40:483-489.
9. de Vries R., Borggreve S.E., Dullaart R.P.F. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003, 49:601-613.
10. Triolo M., Annema W., Dullaart R.P.F., Tietge U.J.F. Assessing the functional properties of high-density lipoproteins-an emerging concept in cardiovascular research. Biomark Med 2013, 7:457-472.
11. Rye K.A., Barter P.J. Cardioprotective functions of HDLs. J Lipid Res 2014, 168-179.
12. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
13. de Vries R., Groen A.K., Dullaart R.P.F. Cholesterol efflux capacity and atherosclerosis. N Engl J Med 2011, 14(364):1473-1474.
14. Li X.M., Tang W.H., Mosior M.K., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013, 33:1696-1705.
15. Hafiane A., Jabor B., Ruel I., Ling J., Genest J. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol 2014, 113:249-255.
16. Patel P.J., Khera A.V., Jafri K., Wilensky R.L., Rader D.J. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011, 58:2068-2075.
17. Willemsen H.M., van der Horst I.C., Nieuwland W., et al. The diagnostic value of soluble CD163 in patients presenting with chest pain. Clin Biochem 2009, 42:1662-1666.
18. Dullaart R.P.F., van Pelt L.J., Kwakernaak A.J., Dikkeschei B.D., van der Horst I.C., Tio R.A. Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain. Clin Chim Acta 2013, 424C:136-140.
19. Nijstad N., de Boer J.F., Lagor W.R., et al. Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice. Biochim Biophys Acta 1811, 2011:294-299.
20. Triolo M., Annema W., de Boer J.F., Tietge U.J., Dullaart R.P.F. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest Dec 11 2013, 10.1111/eci.12226.
21. Acharjee S., Roe M.T., Amsterdam E.A., Holmes D.N., Boden W.E. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2013, 112:1057-1062.
22. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996, 49:1373-1379.